ALPHA 1-ANTITRYPSIN DEFICIENCY
Clinical trials for ALPHA 1-ANTITRYPSIN DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ALPHA 1-ANTITRYPSIN DEFICIENCY trials appear
Sign up with your email to follow new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for rare liver condition
Disease control CompletedThis study tested a new drug called fazirsiran in 16 people with alpha-1 antitrypsin deficiency (AATD) liver disease. The goal was to see if the drug is safe and can reduce harmful protein buildup in the liver. Participants received multiple doses, and researchers measured change…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 06:11 UTC
-
New drug shows promise in reducing Liver-Damaging protein in rare disease
Disease control CompletedThis study tested an experimental drug called fazirsiran in 40 adults with alpha-1 antitrypsin deficiency, a genetic condition that can cause liver and lung damage. The goal was to see if the drug safely lowers levels of a harmful protein (Z-AAT) in the blood. Participants receiv…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 05:49 UTC
-
Early safety check for potential Alpha-1 treatment
Knowledge-focused CompletedThis early-stage study tested a new drug called ARO-AAT in 45 healthy adults to see if it is safe and how the body processes it. The goal was to gather information for future studies in people with Alpha-1 Antitrypsin Deficiency, a genetic condition that can harm the lungs and li…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Knowledge-focused
Last updated May 26, 2026 05:49 UTC